Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Potent CRF1 receptor antagonists and their use described by Yoshitomi

Oct. 21, 1998

Phase I trial for Anergen multiple sclerosis compound demonstrates safety

Oct. 21, 1998

Yamanouchi introduces novel formulation of antiemetic drug

Oct. 20, 1998

First clinical findings presented for Lilly/Synaptic antimigraine drug

Oct. 20, 1998

Dopamine reuptake inhibitors in development at Pola for Parkinson's disease

Oct. 20, 1998

New AMPA and NMDA receptor antagonists in early research at RPR

Oct. 20, 1998

Neurotrophic/neuroprotective agents in development at Sanofi

Oct. 20, 1998

Good efficacy, tolerability reported for Almirall Prodesfarma's antimigraine candidate

Oct. 20, 1998

Statins provide protection against stroke via effects on eNOS

Oct. 20, 1998

Novel CNS technology with broad potential application available from BTG

Oct. 20, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...